Efficacy And Safety Of Adalimumab Biosimilar (Exemptia) In Moderate-To-Severe Steroid-Refractory Ulcerative Colitis Patients: Real-Life Outcomes In Resource-Constrained Setting At 24-Weeks Follow-Up

Efficacy And Safety Of Adalimumab Biosimilar (Exemptia) In Moderate-To-Severe Steroid-Refractory Ulcerative Colitis Patients: Real-Life Outcomes In Resource-Constrained Setting At 24-Weeks Follow-Up

Alok Chandra, Ravi Kanth, Sandeep Thareja Department of Gastroenterology, Base Hospital, New Delhi, IndiaCorrespondence: Ravi KanthDepartment of Gastroenterology, Base Hospital, New Delhi, IndiaEmail ravikanthf2@gmail.comBackground: Adalimumab (ADA) is approved for the management of lcerative coliti...

Full description

Bibliographic Details
Main Authors: Chandra A, Kanth R, Thareja S
Format: Article
Language:English
Published: Dove Medical Press 2019-11-01
Series:Biologics : Targets & Therapy
Subjects:
ulcerative colitis
steroid refractory
adalimumab
biosimilar
exemptia
Online Access:https://www.dovepress.com/efficacy-and-safety-of-adalimumab-biosimilar-exemptia-in-moderate-to-s-peer-reviewed-article-BTT

Internet

https://www.dovepress.com/efficacy-and-safety-of-adalimumab-biosimilar-exemptia-in-moderate-to-s-peer-reviewed-article-BTT

Similar Items